Release of the drug from the bone mineral matrix requires bone resorption, and reduction in bone resorption is the primary mode of action of bisphosphonates. The terminal half-life of alendronate ...

Bisphosphonates (alendronate [Fosamax] and others) inhibit bone resorption and reduce the incidence of fractures in osteoporotic patients during several years of use. However, these drugs ...

This study investigated whether bisphosphonate (Alendronate,ALN) treatment could address bone deficits and arterial calcification in Mgp-null mice. Methods: Mgp-null mice were subjected to various ...

Osteoporosis, a disease that weakens your bones, is also called a “silent” disease because there are no warning signs until a ...

Objectives Concerns have been raised about a possible link between bisphosphonate use, and in particular alendronate, and upper gastrointestinal (UGI) cancer. A number of epidemiological studies have ...

Bisphosphonates play a role in reducing skeletal morbidity in sickle cell disease. Patients with sickle cell disease (SCD) and osteoporosis experience stable bone mineral density (BMD) upon being ...

data to investigate the correlation between oral bisphosphonates (BPs) and oesophageal adverse events (AEs). Methods: We systematically extracted data on adverse reactions to oral alendronate, ...

Among the different options, most experts would choose a bisphosphonate drug like alendronate, based on decades of experience and strong data. However, a very low T-score (worse than -3 ...

The first line of treatment is usually bisphosphonates such as alendronate (Binosto and Fosamax), risedronate (Actonel and Atelvia) and ibandronate (Boniva). These oral or injectable drugs slow ...